Product Description
Mechanisms of Action: Protein Synthesis Inhibitor,Bacterial Growth Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | China | Colombia | Ecuador | Egypt | France | Hong Kong | Indonesia | Korea | Luxembourg | Malaysia | Morocco | Pakistan | Peru | Poland | Portugal | Russia | Saudi Arabia | South Africa | Taiwan | Tunisia | Turkey | Ukraine | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Psyadon Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Respiratory Tract Infections
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
EAAT2 Biomarker | P1 |
Completed |
Healthy Volunteers |
2007-09-01 |
|
2004-001901-81 | P3 |
Terminated |
Respiratory Tract Infections |
None |